News
Big Data & AI For Good Prize: 12th Big Data & AI Paris Congress
We are thrilled to announce that Iktos has won the "Big Data & AI for Good" prize at the 12th edition of the Big...
Kissei Pharmaceutical Introduces Iktos AI Drug Discovery System
Iktos announces that Kissei Pharmaceutical Co., Ltd., a Japanese pharmaceutical company with approximately 75 years of...
Collaboration with Curreio, Inc. in New Drug Discovery
Iktos announces a collaboration with Curreio, Inc., a Japanese company specializing in structural analysis of...
Iktos announces closing of €15.5M in Series A round
Iktos raises € 15.5m Series A round to expand its artificial intelligence-based drug discovery technologies and...
Partnership with MMV in Anti-Malarial Drug Discovery
Iktos announces a collaboration with Medicines for Malaria Venture (MMV), a leading product development partnership...
Collaboration With Galapagos in AI For Drug Design
Iktos announces a collaboration deal with Galapagos, a leading global biopharmaceutical company focused on the...
Iktos & Zealand Pharma to Develop AI Technology for Peptide Drug Design
Iktos today announced a research collaboration with Zealand Pharma A/S, a biotechnology company changing lives with...
Collaboration with Sygnature Discovery in AI for New Drug Design
Iktos and Sygnature Discovery announce their collaboration in Artificial Intelligence for de novo drug design. Under...
Iktos and Teijin Pharma to Co-Develop New Technology for Small Molecule Drug Discovery
Iktos and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides...
Collaboration With Ono in Artificial Intelligence for New Drug Design
Iktos announces a collaboration agreement with Ono Pharmaceuticals Co., Ltd., a leading pharmaceutical company based...
Collaboration with Astrogen to Use AI Platform
Iktos and Astrogen have entered into a research collaboration agreement aimed at discovery of innovative small...
Collaboration with The University of Dundee to Use AI
Under the agreement, Iktos will apply its de novo ligand and structure-based generative modeling technologies, its...